Clinical Trials Logo

Clinical Trial Summary

Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis. Likewise, genetic testing of ovarian cancer patients for these germline mutations provides invaluable information for families regarding cancer risk, genetic testing, and subsequently indication for risk-reducing surgery. Cascade testing provides a unique opportunity to identify carriers of a deleterious BRCA mutation which can allow for surgical and chemoprevention of prevention of ovarian cancer. There is currently no literature on the rates of referral for the family members.


Clinical Trial Description

The objective of this study is to perform a pilot study, offering referral to a genetic counseling and genetic testing for family members of a probands known to have a mutation in BRCA1 or BRCA2. In addition to BRCA1 and BRCA2, the NCCN suggests consideration of risk-reducing surgery for mutations in BRIP1, MSH2, MLH1, MSH6, PMS2, EPCAM, RAD51C, RAD51D, investigators will include these subjects as well in the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04009148
Study type Observational
Source NYU Langone Health
Contact Ashley Brown
Phone 646 501 7629
Email Factsforfam@nyulangone.org
Status Recruiting
Phase
Start date March 1, 2019
Completion date October 30, 2026

See also
  Status Clinical Trial Phase
Completed NCT03377556 - Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Phase 2
Recruiting NCT04294927 - TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention N/A
Recruiting NCT04030559 - Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Phase 2
Not yet recruiting NCT06392841 - Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations Phase 2
Recruiting NCT05420064 - An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk N/A
Recruiting NCT02993068 - Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) N/A
Active, not recruiting NCT03344965 - Olaparib In Metastatic Breast Cancer Phase 2